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Abstract
Small molecule multi-targeted CDK inhibitors (CDKIs) are of particular interest due to their
potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a
very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of
RGB-286638, an indenopyrazole-derived CDKI with Ki-nanomolar activity against transcriptional
CDKs. We examined RGB-286638’s mode-of-action in MM cell lines with wild type (wt)-p53
and those expressing mutant p53. RGB-286638 treatment resulted in MM cytotoxicity in vitro
associated with inhibition of MM tumor growth and prolonged survival in vivo. RGB-286638
displayed caspase-dependent apoptosis in both wt-p53 and mutant-p53 cells that was closely
associated with the downregulation of RNA polymerase II phosphorylation and inhibition of
transcription. RGB-286638-triggered p53 accumulation via nucleolar stress and loss of Mdm2,
accompanied by induction of p53 DNA binding activity. Additionally, RGB-286638 mediated
p53-independent activity, which was confirmed by cytotoxicity in p53-knockdown and p53-
mutant cells. We also demonstrated downregulation of oncogenic miR-19, miR-92a-1, and
miR-21. Our data provide the rationale for the development of transcriptional CDK inhibitors as
therapeutic agents, which activate p53 in competent cells, while circumventing p53 deficiency
through alternative p53-independent cell death mechanisms in p53-mutant/deleted cells.
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tINTRODUCTION
Cyclin-dependent kinases (CDKs) are a family of protein kinases that, upon activation by
their regulatory cyclin partners, coordinate two main cellular processes which are
indispensable for the malignant cell phenotype: cell cycle and transcription1. CDK 1, 2, 3, 4
and 6 are key regulators of cell cycle progression2. CDKs 4 and 6, complexed with cyclin D,
initiate G1 phase-specific transcription by phosphorylating the Rb protein, while CDK2/
cyclin A promotes DNA replication during S phase, and CDK1/cyclin B regulates mitosis.
CDK 1, 2, 7, 8, 9 and 11 share important functions in mRNA transcription, and have all
been implicated in the phosphorylation of the Ser residues at positions 2 (S2) and 5 (S5) of
the C-terminal domain (CTD) of the largest RNA polymerase II (RNAPII) subunit essential
to RNAPII transcriptional activity3. Unlike other CDKs, CDK9 appears to function
exclusively on transcriptional regulation, phosphorylates both RNAPII S2 and S5, and is
critical for transcription elongation of most protein coding genes, including key
developmental and stimulus-responsive genes 4.
The rationale for targeting cyclin-dependent kinases (CDKs) and/or cyclins in multiple
myeloma (MM) originated from comprehensive cytogenetic studies suggesting that
dysregulated and/or increased expression of cyclin D1, D2, or D3 occurs as an early,
unifying event in MM pathogenesis, predisposing MM cells to proliferative stimuli5–7. In
MM, specific inhibition of CDK4/6 by PD 0332991 has demonstrated only growth arrest8.
Effective MM cytotoxicity was best achieved when multiple CDKs were inhibited
concurrently, as with multi-targeted CDK inhibitors such as Seliciclib9, UCN-01,
P276-0010, and AT751911. In addition to their effect against cell cycle specific cyclins and
CDKs, these drugs target transcriptional CDKs, thereby resulting in inhibition/inactivation
of RNAPII.
The primary events of RNAPII inactivation in cells are induction of p53 and decreased
expression of a number of highly expressed anti-apoptotic proteins with a short half life such
as Mcl-1, survivin, and XIAP12–14. This may result in both p53-dependent and -independent
apoptosis. In MM, p53 deletion has been reported in 10% of newly diagnosed MM tumors,
whereas the prevalence is much higher in advanced and extra-medullary tumors, and
associates with a very poor prognosis15, 16. Hence, CDKIs with activity against
transcriptional CDKs, which activate p53 in competent cells, while circumventing p53
deficiency through alternative p53-independent cell death mechanisms in p53-mutant/
deleted cells, are particularly appealing for the treatment of MM.
We examined the anti-MM activity of RGB-286638, a novel compound of the
indenopyrazole family of CDKIs with potent cellular activity against transcriptional-type
CDKs in MM cells. RGB-286638 mediated RNAPII inhibition, induced p53 accumulation,
and triggered cytotoxicity in both wild type (wt)- and mutated-p53 MM cell lines, prompting
us to examine RGB-286638’s mechanism of action in MM cells expressing wt-p53 versus
p53 deficient cells.
MATERIALS AND METHODS
Cell Culture
Dex-sensitive (MM.1S) and -resistant (MM.1R) cells were provided by Dr. Steven Rosen
(Northwestern University, Chicago, IL, USA); H929, RPMI8226, and U266 were obtained
from ATCC (Rockville, MD, USA); OPM1 plasma cell leukemia cells were provided by Dr.
E. Thompson (University of Texas Medical Branch, Galveston, USA). All MM cell lines
were cultured in RPMI-1640 containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/
mL penicillin, and 100g/mL streptomycin. Patient MM primary tumor cells were obtained
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tfrom bone marrow (BM) aspirates in accordance with the Declaration of Helsinki, and with
the approval of the IRB of Massachusetts General Hospital. BM mononuclear cells were
separated using Ficoll-Hipaque density sedimentation, and plasma cells were purified by
positive selection with anti-CD138 magnetic activated cell separation microbeads (Miltenyi
Biotec, San Diego, CA, USA). BM stroma cells (BMSCs) were generated from BM
specimens from MM patients as described previously17. Blood samples collected from
healthy volunteers were processed by Ficoll-Hipaque gradient to obtain peripheral blood
mononuclear cells (PBMCs).
RGB-286638
Was obtained from Agennix USA Inc., Princeton, NJ, USA. For the in vitro experiments the
drug was provided in 20mg/ml aqueous solution.
5,6-Dichloro-1—D-ribofuranosylbenzimidazole (DRB)
DRB was obtained from Sigma-Aldrich, St. Louis, MO, USA.
Cell Viability Assay
Colorimetric assays were performed to assay drug activity at increasing concentrations of
RGB-286638. Cells from 24- or 48-h cultures were pulsed with 10μL of 5mg/mL 3- (4,5-
dimethylthiazol-2-yl) -2,5-diphenyl tetrasodium bromide (MTT; Chemicon International
Inc, Temecula, CA, USA) to each well, followed by incubation at 37°C for 4h, and addition
of 100 μL isopropanol containing 0.04 HCl. Absorbance readings at a wavelength of 570nm
(with correction using readings at 630nm) were taken on a spectrophotometer (Molecular
Devices Corp., Sunnyvale, CA, USA). All experiments were performed in triplicates.
Western Blotting
MM cells were treated with RGB-286638 and harvested; whole cell lysates were subjected
to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA), as described
previously10. Immunoblotting was performed using specific antibodies: anti-phosphorylated
(p)-RNAPII S2, -p-RNAPII S5 and -RNAPII (8WG16) (Covance); anti-p-Rb S807/811, -p-Rb
S780, -p-GSK3 α/β S21/9, -GSK3 β, -p-STAT3 S727, -STAT3, -p-GS S641, -p-TAK1 T184/187,
-p-c-FMS T809, -p-p53 S15, -CDK1, -CDK4, -Cyclin D1, -CDK6, -Cyclin D3, -CDK2, -
XIAP, -cleaved caspase 8, 9, and 3, -PARP (Cell Signaling Technology, Beverly, MA,
USA); as well as anti-p-ERK1/2, -Cyclin B1, -Cyclin E, -Cyclin A, -Mcl-1, -p53 (DO-1), -
Mdm2 (Santa Cruz Biotech, Santa Cruz, CA, USA). Blots were re-probed with the anti-actin
(Santa Cruz Biotech), anti-tubulin, or -GAPDH (Cell Signaling Technology) antibodies for
equal protein controls.
Cell Cycle Analysis
MM.1S cells (1 × 106) cultured in media alone, or with 50nM RGB-286638, were washed
with ice-cold PBS, fixed with 100% ethanol for 1h at 4°C, and pretreated with RNase DNase
free (Roche Diagnostics Corporation, Indianapolis, USA) for 30min at 37°C. Cells were
stained with PI (5g/mL; Sigma Chemical), and cell cycle profile was determined using the
BD Diva software on BD LFR2 flow cytometer (San Jose, CA, USA). Analysis of the data
was done using ModFit cell cycle analysis program.
Detection of Apoptosis
Apoptosis detection was performed with the annexin V-PI detection kit (Immunotech/
Beckman Coulter). MM.1S cells (1 × 106) were exposed for 12–24h to RGB-286638
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t(50nM). Cells were then incubated with annexin V-FITC and PI for 15min. Annexin V+PI+
positive apoptotic cells were enumerated using BD LFR2 flow cytometer (San Jose, CA,
USA).
MM Xenograft Murine Model
The in vivo anti-MM activity of RGB-286638 was evaluated in a previously established MM
xenograft model10. RGB-286638 dosing solutions of 2 and 3 mg/ml in 5% dextrose/water
(D5W) pH5.2, as well as D5W pH5.2 for vehicle control dosing group, were prepared and
provided by Agennix AG. CB-17 severe combined immunodeficient (SCID) mice (Charles
River Laboratories, Wilmington, MA, USA) were monitored in the Animal Research
Facility at DFCI, and subjected to studies approved by the Animal Ethics Committee. Forty
male 5–6 week old mice were irradiated (2 Gy [200 rad]) using cesium 137 (137Cs)-
irradiator source); 24h after irradiation, 2.5 × 106 MM.1S cells were inoculated
subcutaneously in the upper back. When tumor weight was approximately 100mg, mice
were randomly assigned into 3 cohorts receiving daily IV tail vein injections for 5
consecutive days with either RGB-286638 30mg/kg (8 mice), 40mg/kg (9 mice), or control
vehicle alone (10 mice). Animals were monitored for body weight and tumor volume by
caliper measurements every alternate day. Tumor volume was estimated using the following
formula:  . Animals were euthanized in accordance with DFCI
Animal Care and Use Committee guidelines by CO2 inhalation in the event of tumor size >
2cm or due to tumor ulceration. Survival was evaluated from the first day of treatment until
death. Tumor growth was evaluated using caliper measurements from the first day of
treatment until day of first sacrifice. Percentage tumor growth inhibition (TGI) was
calculated as TGI on day X = 100 − T/C% on day X. Log10 cell kill was calculated by the
formula  .
RNA Synthesis Assay
Synthesis of RNA was evaluated by measuring the incorporation of [5′-3H]uridine (5μCi/
ml) (Perkin Elmer, Boston, MA) into MM.1S, U266, OPM1 and RPMI cells, as described
previously11. MM cells (2–3 × 103 cells/well) were incubated in 96-well culture plates alone
or with BMSCs, with varying concentrations of RGB-286638 for 8 or 24 h at 37°C.
[5′-3H]uridine was added (1 mCi (37 KBq) per well) prior to harvesting with the automatic
cell harvester (Cambridge Technology, Cambridge, MA, USA), then counted using the LKB
Betaplate scintillation counter (Wallac, Gaithersburg, MD, USA). [5′-3H]uridine assays
were performed in triplicate.
DNA Synthesis Assay
DNA synthesis was measured by tritiated thymidine uptake [3H-TdR] (Perkin Elmer,
Boston, MA, USA) as previously described10, 18. MM.1S cells (2–3 × 103 cells/well) were
incubated alone or with BMSCs in 96-well culture plates with varying concentrations of
RGB-286638 for 24-, or 48-h at 37°C. Cells were pulsed with [3H-TdR] (0.5 mCi per well)
during the last 8h of the end time point, harvested with an automatic cell harvester
(Cambridge Technology, Cambridge, MA, USA), and counted by using the LKB Betaplate
scintillation counter (Wallac, Gaithersburg, MD, USA). All experiments were performed in
triplicates.
RNA Extraction
For miRNA expression profiling, MM.1S cells alone or in co-culture with BMSCs were
incubated for 8h in control media or RGB-286638 (50nM). Similarly, MM.1S, OPM1, U266
and RPMI cells were cultured 8h in media alone or 50nM RGB-286638 for miRNA Specific
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tAssays. Total RNA was extracted from MM cell pellets using mirVana miRNA Isolation Kit
(Ambion, Inc), according to the manufacturer’s protocol.
miRNA Expression Profiling Using Human TaqMan Low Density Array Cards
miRNA expression profiling was performed on MM.1S cells cultured for 8h in control
media or 50nM RGB-286638, with or without BMSCs. TaqMan® Low-Density Array
(TLDA) using human miRNA version 2.0A and version 3.0B cards (Applied Biosystems,
Foster City, CA, USA) was applied to examine the global change in miRNA expression
levels in MM.1S cells when co-cultured with BMSCs, with or without RGB-286638
treatment. A total of 756 mature miRNA updated in the Sanger miRBase v.15.0 were
quantified, as previously described 19, 20. miRNAs with Ct values higher than 35 were
excluded from the analysis. Normalization was carried out with the mean of RNU44 and
RNU48. Relative quantification (RQ) of miRNA expression was calculated with the 2−ΔΔCt
Ct method using the ddCt program.
Real-Time PCR Detection and Quantification of Specific miRNA
To evaluate miR-19, miR-92a-1, and miR-21 expression in p53-wt MM.1S along with p53-
mutated U266, RPMI, OPM1 cells with or without 8h RGB-286638 (50nM) treatment, we
used target-specific TaqMan® MicroRNA Assays (Applied Biosystems, Foster City, CA,
USA), in accordance with the manufacturer’s protocols. The 2−ΔΔCt method was used to
calculate relative changes in miRNA expression. The results were normalized to levels of
miRNA endogenous control (RNU48-001006).
Nucleolar Segregation Analysis
Was performed using The Total Nuclear-ID™ Red/Green Nucleolar/Nuclear Detection Kit
(Enzo Life Sciences International, Inc; Plymouth Meeting, PA, USA). Pre-treated with
RGB-286638 (50nM) for 3h, MM.1S cells were then incubated with 100μL Dual Detection
Reagent for 30 min at 37°C. Live stained cells were analyzed by immunofluorescence
microscopy (60X magnification), using a standard FITC filter set for imaging the nucleolus,
and a standard Texas Red filter set for the counterstained nucleus.
Sequence Specific P53 DNA Binding Assay
Detection of p53 sequence specific DNA binding activity was performed using the p53
Transcription Factor Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA)
according to the manufacture’s protocol. Nuclear proteins were isolated from MM.1S cells
treated with 50nM RGB-286638 for 1, 4, and 8 h, using Nuclear Extraction Kit (Affymetrix
Inc, Santa Clara, CA, USA). Nuclear protein aliquots were added to the 96-well plate coated
with specific double-stranded DNA sequence containing the p53 response element for
overnight incubation. p53 in the nuclear extract was detected by addition of a specific
primary antibody directed against p53. A secondary antibody conjugated to HRP was added
to provide a sensitive colorimetric readout at 450 nm. All experiments were performed in
triplicates.
NAD+/NADH Assay
NAD+/NADH quantification assay (BioVision, Mountain View, CA, USA) was performed
in MM.1S cultured with RGB-286638 (50nM). A total of 5 × 105 cells were used for the
NAD+/NADH extraction. Duplicates of extracted samples (50μL) were transferred into a
96-well plate and incubated at RT for 5min with 100μL of NAD Cycling Mix, to allow the
conversion of NAD+ to NADH. Extracted solution (200μL) from each sample was heated at
60°C for 30min for NAD+ decomposition. Duplicates of each NADH sample (50μL) were
transferred to a 96-well plate, 10μL/well NADH developing solution was added; after 40min
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tin the dark, the plate was read at 450nm wavelength on a microplate reader. The ratio of
NAD+/NADH was calculated as follows: (NADt − NADH)/NADH.
Lentivirus-Mediated Knockdown of p53
Lentiviral particles expressing shRNA against human TP53 gene (clone name
NM_000546.x-941s1c, targeted sequence CACCATCCACTACAACTACAT) were
obtained from the Broad Institute (MIT, Boston, MA, USA) and transduced according to the
manufacturer’s protocol. Briefly, supernatants containing shTP53 or empty vector lentiviral
particles were added to exponentially growing MM.1S in media containing polybrene (8μg/
ml). Fresh medium was supplemented at 24h after infection. The infectivity was determined
after 72h by comparing the differential sensitivity to puromycin (2μg/ml) treatment between
parental and transduced cells, as assessed by MTT assay.
RESULTS
RGB-286638 Demonstrated Potent Activity against Transcriptional CDKs in MM Cell Lines
and Inhibited Myeloma Cell Growth in Vitro
To assess RGB-286638’s potential anti-MM activity, we first investigated the in vitro effects
of RGB-286638 treatment in MM cell lines and primary tumor cells from MM patients.
RGB-286638 is a novel compound of the indenopyrazole family of CDK inhibitors (Fig.
1A) that inhibited the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2,
cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 (IC50, 1, 2, 3, 4, and 5 nM, respectively),
and was less potent against cyclin H-CDK7 and cyclin D3-CDK6, as demonstrated by in
vitro kinase profiling21. Additionally, RGB-286638 inhibited several tyrosine and serine/
threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1 (Table 1). We
investigated the dose- and time-dependent effect of treatment with RGB-286638 (12.5–
100nM) on the growth of human p53-wt (MM.1S, MM.1R, and H929) and p53-mutant
(U266, OPM1, and RPMI) MM cells by MTT assay, assessing viability at 24 and 48 hours.
The half-maximally effective concentrations (EC50) ranged between 20 and 70 nM at 48
hours. Dose-dependent differences in growth among p53-wt and -mutant cells were
observed after 50nM treatment, with p53-wt MM.1S, MM.1R and H929 being slightly more
sensitive to RGB-286638 treatment at 48h (Fig. 1B). Moreover, RGB-286638 demonstrated
equimolar (50nM) activity in freshly isolated tumor cells from MM patients, while
manifesting less cytotoxicity in healthy donor PBMCs (Suppl. Fig. S1). Next, we examined
RGB-286638 (50nM) activity against transcriptional CDK7/9 and cell cycle-related CDK4/6
in MM cells based on phosphorylation of their RNAPII S2/S5 and Rb S780/S807/811
substrates, respectively. Using time- and dose-dependent (0–8h; 25–100nM) immunoblot
analysis, we found that treatment with RGB-286638 resulted in rapid downregulation of p-
RNAPII S2/S5 across all tested MM cell lines. RGB-286638 (50nM) reduced the
phosphorylation of Rb at S807/811 in MM.1S and MM.1R cells, but had no effects on p-Rb
S780.
We next evaluated the effects of RGB-286638 treatment on the activity of selective non-
CDK enzymes (Suppl Fig. S2). Immunoblot analysis of MM cell lines treated with 50nM
RGB-286638 revealed increased phosphorylation of the α subunit of GSK3 at Ser21, but
decreased phosphorylation of β subunit at Ser9 (Fig. S2-A). Phosphorylated GS at S641, a
downstream target of GSK3β, remained unchanged at 4–8h in all cell lines except U266,
where it was decreased (Fig. S2-B). Next, 50nM RGB-286638 did not affect the
phosphorylation of T184/187 residues in the activation loop of TAK1; c-FMS T809
phosphorylation was slightly reduced in MM.1R and OPM1 cells (Suppl. Fig. S2-C). We
also evaluated RGB-286638 effects on JAK2 and MAPK signaling by examining p-STAT3
S727 and p-ERK1/2 in cells exposed to increasing concentrations of RGB-286638 for 4h
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t(Fig. S2-A). RGB-286638 treatment did not affect STAT3 S727. Moreover, short exposure to
RGB-286638 resulted in upregulated p-ERK1/2 in MM.1R, H929, and U266 cells.
RGB-286638-Induced Apoptosis in Vitro Translated to Anti-MM Activity in Vivo
We next examined the molecular mechanisms underlying RGB-286638-mediated
cytotoxicity in p53-wt (MM.1S) and p53-mutant (U266) cells, specifically examining the
effects on cell cycle related proteins, and apoptosis. Time-course immunoblot analysis
revealed that 50nM RGB-286638 treatment decreased cyclins (A, B1, D1, and D3), CDK1,
and CDK4 expression in MM.1S cells, and reduced cyclin A and D1 levels slightly in U266
cells within 8h (Fig. 2A). As expected, 50nM RGB-286638 reduced the expression of the
anti-apoptotic proteins Mcl-1 and XIAP. Caspase-8, -9, -3 and PARP cleavage occurred
within 4h in both MM.1S and U266 cell lines (Fig. 2B). DNA cell cycle analysis of MM.1S
cells treated with RGB-286638 (50nM) revealed G1 and G2/M cell cycle arrest at 12h,
followed by sub-G1 fraction at 24h (Fig. 2C). Apoptosis was confirmed by Annexin/PI
staining, which demonstrated increased apoptotic MM cells, 25% and 45% at 12 and 24
hours, respectively (Fig. 2D). This in vitro RGB-286638-induced MM cytotoxicity
translated into effective in vivo anti-MM activity in SCID mice xenografted MM.1S cells
(Fig. 2E). Dose-finding studies (data not shown) with RGB-286638 identified 40mg/kg/day
IV treatment as the maximum tolerated dose in SCID mice. Five days IV treatment with
RGB-286638 significantly suppressed MM tumor growth, with maximum TGI (%) noted at
day 14 following end of treatment at 85.06% and 86.34% in the 30 mg/kg and 40 mg/kg
treated cohorts respectively. The log10 cell kill (LCK Td: 4.5 days) was 1.6 for both treated
groups. RGB-286638 treatment was also associated with improved survival, evidenced by
first death at day 24 in controls versus day 43 in both treated groups (Fig. 2E lower panel).
No toxic deaths occurred during this study: maximum percentage of body weight (BW) loss
was observed on day 5 (8.4%) at 30mg/kg dosage schedule, and on day 15 (9.9%) after 40
mg/kg dosing, with weight recovery in the following two weeks.
RGB-286638 Inhibited Transcription
We next investigated effects of RGB-286638 on transcription in MM.1S cells. Since
RGB-286638 (50–100nM) reduced RNAPII phosphorylation by 2h (Fig. 3A), and since
phosphorylation of the CTD of RNAPII by CDK9/cyclin T is required for transcriptional
elongation 22, 23, we assessed the rate of RNA synthesis. Two hours of RGB-286638 (50nM
or 100nM) treatment reduced RNA synthesis by 50% (Fig. 3A). Since the BM
microenvironment induces transcription and proliferation in MM cells24, 25, we next
examined the effect of treatment on the rate of RNA and DNA synthesis in MM.1S cells,
alone or cultured with patient-derived BMSCs. Using RNA synthesis assay, we found that
RGB-286638 reduced the total level of transcripts in BMSCs-stimulated MM.1S cells by
~50% at 8h, and ultimately blocked transcription at 24h (Fig. 3B), associated with marked
(60%) reduction in DNA synthesis at 8h and complete block of MM.1S proliferation at 24h
(Fig. 3C).
RGB-286638 Triggered Stabilization and Activation of p53
Since RGB-286638 inhibited transcription, and since transcriptional inhibitors can induce
p53 accumulation via reduction in Mdm2 expression, we next examined effects of
RGB-286638 on p53 and Mdm2 expression in MM cells. Time-course western blot analysis
of p53-wt (MM.1S, MM.1R, H929) and p53-mutated (U266, OPM1, RPMI) MM cells
treated with 50nM RGB-286638 showed decreased Mdm2 expression in all cell lines,
associated with upregulated p-p53 S15 and p53 levels in p53-wt, but not in p53-mutated, cell
lines (Fig. 4A). We next compared the effects of RGB-286638 to the previously described
transcription inhibitor DRB on p53 and Mdm2 expression. Similar to RGB-286638, DRB
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t(2h) significantly inhibited RNA synthesis in MM.1S cells (Suppl. Fig. S3). Western blot
studies of MM.1S treated with increasing concentrations of RGB-286638 or DRB for 2h
triggered p53 accumulation without affecting Mdm2 levels at doses that inhibited RNAPII
phosphorylation and reduced transcription (Fig. 4B).
Previous studies linked nucleolar stress and transcriptional arrest to p53 accumulation.
Specifically, transcriptional arrest due to RNA polymerase dephosphorylation triggers
nucleolar reorganization and nucleolar segregation26. Immunofluorescence microscopy
revealed that the nucleoli (green staining) of cells exposed to 3h RGB-286638 treatment
formed numerous speckles of fluorescence spread all over the nucleus (red staining)
suggesting nucleolar segregation (Fig. 4C). Re-localization of nucleolar compartments
during segregation is an energy-dependent repositioning process27. We therefore
investigated whether RGB-286638 treatment affected the status of nicotinamide nucleotides
(NAD/NADH), markers of energy transforming processes. By NADt/NADH quantification
assay RGB-286638 treatment resulted in 30% NADt/50% NADH depletion (Suppl. Fig. S4).
Western blot analysis of nuclear and cytoplasmic extracts from RGB-286638-treated MM.
1S cells showed accumulation of p-p53 S15 and total p53 predominantly in the nuclear
compartment (Fig. 4D).
We next examined whether p53 stabilization associated with p53 activation in RGB-286638-
treated MM.1S cells. Increased p53 transcriptional activity via enhanced sequence specific
DNA binding is essential to p53-dependent apoptosis28. P53 sequence specific DNA binding
assay evidenced increased p53 DNA binding and transcriptional activation following 4h
treatment with 50nM RGB-286638 in MM.1S cells (Fig. 4E). We confirmed this finding in
p53-wt MM.1R cells as well (data not shown).
RGB-286638 Mediated p53-Independent Apoptosis in MM Cells
We next tested whether RGB-286638-induced cell death was independent of p53 pathway
activation. Knockdown of p53 by p53-targeting shRNA lentiviral constructs rescued 14%
cells from RGB-286638-induced cell death (Fig. 5A). No significant effect on p-RNAPII
was observed, suggesting that RNAPII activity was independent of p53 status. P53-
independent RGB-286638 activity was further validated by its cytotoxic effects in p53-
mutated U266, OPM1, and RPMI MM cell lines. As measured by [5′-3H]uridine
incorporation, 2h exposure to increasing doses of RGB-286638 reduced RNA synthesis in
p53-mutated MM cell lines, with significant inhibition at 24h (Fig. 5B). As expected,
western blot studies of p53-mutated U266, OPM1 and RPMI cells showed that RGB-286638
treatment consistently reduced Mcl-1 levels, which preceded PARP cleavage (Fig. 5C).
RGB-286638 Modulated miRNA Expression
RNAPII is a key regulator of miRNA synthesis, and RGB-286638 treatment resulted in
early and potent inhibition of RNAPII activity. Moreover, recent studies suggest a strong
correlation between dysregulated miRNA and high-risk myeloma29, 30. We therefore next
examined the effect of the BMSC-MM cell interaction on miRNA. We performed TLDA-
based miRNA expression profiling in MM.1S cells cultured for 8h with or without BMSCs,
in the presence or absence of 50 nM RGB-286638. Our data demonstrated that RGB-286638
treatment modulated BMSCs-induced miRNA expression (Suppl Fig. S5). Among
microarrays identified with significant RQ values, we selected miR-21-3p and miR-19a-5p,
which have been associated with tumorigenesis in MM31–33. Both were decreased in MM.
1S cells in culture with BMSCs after RGB-286638 treatment as confirmed by miR-21-3p
and miR-19a-5p TaqMan Specific miRNA Assays (Fig. 6A).
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(miR-19a and miR-92a-1) in p53-mutated MM cells after RGB-286638 treatment. We
assayed U266, OPM1, and RPMI cells exposed to RGB-286638 treatment (50nM for 8h)
using the TaqMan Specific microRNA assay for miR-21-3p, miR-19a-5p, and
miR-92a-1-5p. RGB-286638 treatment significantly reduced miR-21-3p, miR-19a-5p, and
miR-92a-1-5p levels in U266 and OPM1 cells (Fig. 6B).
DISCUSSION
It is widely accepted that the diverse effects of CDK inhibitors are due to their activity
against multiple CDKs involved in both cell cycle and transcription regulation. Although
most clinically evaluated CDK inhibitors target several CDKs, it has been proposed that the
induction of apoptosis arises primarily due to inhibition of transcriptional-type CDKs34.
Inhibition of transcriptional CDKs, in particular CDK9, leads to the downregulation of
transcriptionally inducible genes with short half-lives, including cell cycle regulators and
anti-apoptotic factors35.
Our study found CDK9 to be among the primary targets of RGB-286638 mediating its pro-
apoptotic activity in MM cells. In vitro kinase assays showed that RGB-286638 is a potent
inhibitor of CDK 1, 2, 3, 4, 5, and 9; as well as 44- and 55-fold less active against CDK 7
and 6, respectively. Kinase profiling of RGB-286638 identified additional inhibition of
distinct serine/threonine and tyrosine protein kinases, predicting modulation of GSK3,
STAT3 and MAPK signaling. In MM cells, however, RGB-286638 demonstrated
preferential inhibition of CDK9 over other targets. The IC50 of RGB-286638 inhibited MM
cell proliferation (50–100 nM) and dephosphorylated RNAPII S2/S5, but did not STAT3
modulate phosphorylation of Rb, and ERK1/2 proteins. We noted that p-Rb S780 site, which
is phosphorylated by several kinases including cyclin D-dependent kinases, was not affected
by RGB-286638 treatment. Importantly, S807/811 phosphorylation of Rb was targeted by
RGB-286638 in MM.1S and MM.1R cells. Recent evidence suggests that physical
interaction between CDK9 and Rb is associated with CDK9-mediated phosphorylation of
Rb on its C-terminus793–928 36; therefore, RGB-286638-mediated inhibition of p-Rb S807/811
may be triggered by inhibition of CDK9 activity. These findings, together with
RGB-286638-induced transcriptional arrest and caspase-dependent apoptosis in MM cell
lines, suggest that inhibition of transcriptional CDK, in particular CDK9, is the primary
mechanism of action of RGB-286638 in MM cells.
Inhibition of RNAPII-mediated transcription was among the early cellular responses that we
detected after RGB-286638 treatment. The blockade of RNA synthesis has been proposed to
be an inducer of p53 accumulation12. In our study, RGB-286638 treatment increased p53
levels in MM cells in a manner similar to the transcriptional inhibitor DRB. However, the
exact molecular mechanisms of inhibited RNAPII and blocked transcription leading to p53
protein stabilization remain unclear. An important trigger seems to be the reduction in
Mdm2 mRNA and protein levels37. Normally, p53 expression is kept low mainly by
interactions with its major regulator Mdm2, which serves as an E3 ubiquitin ligase for p53
and targets p53 for degradation via the 26S proteasome. Hence, depletion of Mdm2
inevitably leads to p53 stabilization and accumulation. We, however, found that
RGB-286638-mediated RNAPII inhibition was associated with increased p53 expression
before Mdm2 was downregulated, consistent with studies showing that blockade of
transcription can induce nuclear accumulation of p53 without downregulation of Mdm2
levels38. Specifically, nucleolar fragmentation significantly reduces the levels of 45S
precursor ribosomal RNA, leading to increased cellular levels of free ribosomal proteins,
some of which (RPL5, RPL11, and RPL23) then bind to the central regulatory domain of
Mdm2 protein and inhibit Mdm2-mediated p53 degradation39–41. Taken together with our
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nucleolar stress and depletion of Mdm2, both mediated through transcriptional arrest, may
contribute to p53 induction in MM cells.
The role of p53 induction in the apoptotic response to CDK inhibitors is controversial. In
our study, RGB-286638-induced p53 nuclear accumulation associated with increased p53
DNA binding activity. Increased p53 transcriptional activity via enhanced sequence specific
DNA binding is essential to p53-dependent apoptosis28. In fact, p53 knockdown rescued
14% cells from RGB-286638-mediated cell death, suggesting p53 played a role in
RGB-286638 cytotoxicity. That may in part explain the observed differential response to
RGB-286638 between p53-wt and p53-mutant cell lines.
Additionally, RGB-286638 displayed p53-independent cytotoxicity and caspase-dependent
apoptosis induction in p53-mutant cells were closely associated with downregulation of
RNAPII phosphorylation and inhibition of transcription. RNAPII’s control over miRNA
transcription, together with recent findings that miR-19, miR-92a-1, and miR-21 miRNAs
play a role in MM tumorigenesis, prompted us to examine effects of RGB-286638 on
expression of these miRNAs. Our data shows downregulation of oncogenic miR-19,
miR-92a-1, and miR-21 associated with reduced expression of Mcl-1 following RNAPII
transcriptional arrest in U266 and OPM1 p53-mutant cells, suggesting a contributory effect
to p53-independent MM cytotoxicity.
In conclusion, our data provide the rationale for the development of transcriptional CDK
inhibitors as anti-MM agents that activate p53 in competent cells, while circumventing p53
deficiency through alternative p53-independent cell death mechanisms in p53-mutant/
deleted cells.
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tFigure 1. RGB-286638 Demonstrated Potent Activity Against Transcriptional CDKs in MM Cell
Lines and Inhibited Myeloma Cell Growth in Vitro
(A) RGB-286638 chemical structure (left panel). Chemical name: 1-(3-{4-[4-(2-
Methoxyethyl)-piperazin-1-ylmethyl]-phenyl}-4-oxo-1,4-dihydroindeno[1,2-c]pyrazol-5-
yl)-3-morpholin-4-yl-urea dihydrochloride. Molecular formula: C29H37N7O4 2HCl.
Molecular weight: 618.52.
(B) Dose- and time-dependent cytotoxicity of RGB-286638 in MM cell lines. Expressing
wild-type p53 (MM.1S, MM.1R, H929) or mutant-p53 (U266, OPM1, RPMI) cells were
incubated with RGB-286638 (0–100nM), and viability was determined at 24 and 48 h using
MTT assay. EC50 ranged between 20–70nM at 48h.
(C) RGB-286638-mediated cytotoxicity in primary tumor cells from MM patients.
Myeloma cells isolated from BM via CD138+ positive selection were cultured with
RGB-286638 (0–100nM), and viability was assessed by MTT at 48h. RGB-286638
demonstrated comparable cytotoxicity to MM cell lines. Data represents means (+/−SD) of
triplicate cultures.
(D) RGB-286638 treatment results in transcriptional CDK inhibition. The indicated cell
lines were exposed to RGB-286638 (0–100nM) 1, 4, and 8 h treatment. Whole lysates were
subjected to western blotting and membranes probed for phosphorylated RNAPII at S2/S5
and Rb at S807/811/S780 sites using phosphospecific antibodies.
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tFigure 2. RGB-286638-Induced Cytotoxicity in Vitro Translates in Anti-MM Activity in Vivo
(A) RGB-286638 reduced the expression of cell cycle related proteins. MM.1S and U266
cells were treated with 50nM RGB-286638 for 2, 4, and 8 h, and whole cell extracts
resolved by SDS-PAGE. Cell cycle-related proteins were assessed through probing
membranes with the indicated antibodies.
(B) Treatment with RGB-286638 reduced anti-apoptotic protein expression and
triggered caspase and PARP activation. The expression of RNAPII anti-apoptotic Mcl-1
and XIAP transcripts was examined by western blot in MM.1S and U266 cells treated with
50nM RGB-286638 (0–8h). After 4, 8, and 24 h RGB-286638 (50nM) treatment, MM.1S
and U266 cells were subjected to western blotting for detection of caspase 8, 9, 3 and PARP
cleavage.
(C) RGB-286638 affected cell cycle progression. Cell cycle progression was examined via
flow cytometry in MM.1S cells stained with propidium iodide after exposure to media alone,
or to 50nM RGB-286638 for 12 and 24 h. RGB-286638 treatment affected G1/S and G2/M
cell cycle progression.
(D) RGB-286638 induced early time point apoptosis. Annexin/PI staining and FACS
analysis for apoptosis was performed on MM.1S cells cultured with or without 50nM
RGB-286638 for 12 and 24 h. Viable cells are represented in the lower left quadrants.
Increasing percentages of apoptotic cells after prolonged exposure to RGB-286638
treatment are shown in the lower and upper right quadrants.
(E) RGB-286638 anti-MM activity in vivo: tumor growth, host weight, and Kaplan–
Meier survival curves in xenografted with MM.1S cells mice. SCID mice were
inoculated subcutaneously with 3 × 106 MM.1S cells in 100 uL RPMI medium. Tumor-
bearing mice were randomly assigned into 3 cohorts receiving daily IV tail vein injections
for 5 consecutive days with 30 mg/kg or 40 mg/kg RGB-286638, or with control vehicle
alone. RGB-286638 treatment resulted in tumor growth inhibition. Transient weight loss,
with maximum body weight loss on day 5 (8.4%) after 30 mg/kg and on day 15 (9.9%) after
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t40mg/kg dosing, was followed by recovery in the following two weeks. Prolonged survival
was observed in both 30 mg/kg and 40 mg/kg dosing groups.
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tFigure 3. RGB-286638 Inhibited Transcription
(A) RGB-286638 inhibited RNAPII-mediated transcription. MM.1S were incubated with
RGB-286638 (0–100 nM) for 2 hours. Whole cell lysates were subjected to western blotting
and analyzed using specific antibodies for p-RNAPII S2, RNAPII, and GAPDH. RNA
synthesis was evaluated in MM.1S cells pre-incubated for one hour with the indicated
concentrations of RGB-286638. [5′-3H]uridine was added, and after one hour incubation
cells were assayed for radioactivity. Data represent means (+/−SD) of triplicate cultures.
(B) RGB-286638 reduced BMSC-induced RNA synthesis in MM.1S cells. Cells were
incubated with increasing concentrations of RGB-286638 for 8 and 24 h, alone or in co-
culture with BMSCs; [5′-3H]uridine was added and RNA synthesis measured. Data
represent means (+/−SD) of triplicate cultures.
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t(C) RGB-286638 abrogated BMSC-induced DNA synthesis in MM.1S cells. MM.1S
cells, in the presence or absence of BMSCs, were treated with increasing concentrations of
RGB-286638 for 8 and 24 h; cell proliferation was then examined by [3H-TdR] uptake. Data
represents means (+/−SD) of triplicate cultures.
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tFigure 4. RGB-286638 Triggered Stabilization and Activation of p53
(A) RGB-286638 induced p53 accumulation and reduced Mdm2 expression in wt-p53
MM cells. P53 levels remained unchanged in mutant-p53 MM cells, regardless of
reduced Mdm2. Wt-p53 MM.1S, MM.1R, and H929, and mutant-p53 U266, OPM1, and
RPMI cells were exposed to 50nM RGB-286638 for 0–8 h, and whole cell extracts then
subjected to western blotting. Expression of p-p53 S15, p53, Mdm2, and GAPDH was
determined using specific antibodies.
(B) RGB-286638 triggered p53 accumulation prior to reducing Mdm2. p53 and Mdm2
expression were correlated with RNAPII inhibition in MM.1S cells cultured for 2h with
control media, or with increasing concentrations of RGB-286638 (0–100nM) or DRB (0–
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t60uM). Whole cell extracts were examined via western blotting for expression of p-RNAPII
S2, RNAPII, p-p53 S15, p53, and GAPDH.
(C) RGB-286638 induced nucleolar fragmentation. MM.1S cells incubated with
RGB-286638 (50nM) or media alone for 3 hours were pelleted and re-suspended in 100 μL
Dual Detection Reagent for 30 min. Viable cells were analyzed by immunofluorescence
microscopy (60X magnification).
(D) RGB-286638 triggered nuclear accumulation of p53. Nuclear and cytoplasmic
extracts separated from MM.1S cells exposed to 50nM RGB-286638 for 0–8 h were
analyzed by western blotting for expression of p-p53 S15 and p53 using specific antibodies.
Expression of p84, or α-tubulin was used for loading control of nuclear or cytoplasmic
proteins, respectively.
(E) RGB-286638 increased p53 sequence specific DNA binding activity. P53/DNA
binding activity was detected in nuclear extracts purified from MM.1S cells cultured with
media, or RGB-286638 (50nM) for 1, 4, and 8 h. Data represents means (+/−SD) of
triplicate cultures.
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tFigure 5. RGB-286638 Mediated p53-Independent Apoptosis in MM Cells
(A) RGB-286638 induced cytotoxicity in p53 knockdown MM.1S. P53 shRNA- or empty
vector-transduced MM.1S were cultured with RGB-286638 (0–100nM) or 1.5ug/ml
puromycin for 48h, and viability was assayed using MTT. Data represent means (+/−SD) of
triplicate cultures. P53 and p-RNAPII S2 were examined by western blotting of whole cell
lysates of parental MM.1S cells and MM.1S cells transduced with p53 shRNA or with
empty vector.
(B) RGB-286638 reduced transcription in mutant-p53 MM cell lines. U266, OPM1, and
RPMI cells were treated for 2 and 24 h with RGB-286638 (0–100nM); [5′-3H]uridine was
then added, and RNA synthesis measured. Data represent means (+/−SD) of triplicate
cultures.
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t(D) RGB-286638 triggered apoptosis in MM cell lines expressing mutant-p53. U266,
OPM1, and RPMI cells incubated with or without 50nM RGB-286638 for 1, 4 and 8 h were
examined by western blotting with anti-Mcl-1, -PARP, and - GAPDH antibodies.
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tFigure 6. RGB-286638 Effects on miRNA Expression
(A) RGB-286638 modulated miRNA expression in MM.1S cells alone and in culture
with BMSCs. TaqMan® miR-21-3p and miR-19a-5p miRNA Specific Assays using RT-
PCR were performed on aliquots of total RNA extracts from MM.1S cells cultured for 8h in
control media or 50nM RGB-286638, with or without BMSCs. Data are presented as
relative quantity (RQ) values in RGB-286638 treated versus untreated cells. The
experiments were carried out in triplicates, (*) if p<0.05 and two (**) if p<0.01.
(B) RGB-286638 suppressed the expression of the oncogenic miR-19a-5p, miR-21-3p,
and miR-92a-1-5p in mutant-p53 MM cell lines. U266, OPM1, and RPMI cells were
incubated in media alone or in 50nM RGB-286638 for 8h. Total RNA extracts were
subjected to TaqMan Specific miRNA Assays for miR-21-3p, -19a-5p, and -92a-1-5p
detection. Data is presented as RQ values of RGB-286638-treated versus -untreated cells.
Experiments were carried out in triplicates, (*) if p<0.05 and two (**) if p<0.01.
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Table 1
RGB-286638 Kinase Profiling
CDKs IC50 (nm) non-CDKs IC50 (nm)
K9/T1 1 Fms 1
K1/B1 2 GSK-3β 3
K2/E 3 TAK1 5
K4/D1 4 JNK1a1/2 17/40
K3/E 5 C-src 25
K5/p35 5 AMPK 41
K7/H 44 Jak2 50
K6/D3 55 MEK1 54
Note: RGB-286638 multi-targeted kinase activity as measured by in vitro cell-free kinase assays.
Table 1 contains the IC50 kinase inhibition Ki (nM) of individual CDKs and selected tyrosine and serine/threonine kinases (determined in
biochemical kinase assays).
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